Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone FA6-152] (IgG1) to Human CD36
IHC - Frozen, Immunofluorescence, Immunoprecipitation, Flow Cytometry, Functional Assay (applications tested for the base form of this product only)
Human (tested or 100% immunogen sequence identity)
IgG1 Monoclonal [FA6-152]
IHC - Frozen
(applications tested for the base form of this product only)
Specificity and Use
CD36 antibody was raised against fetal erythrocytes
The applications listed have been tested for the base form of this product. Alternate forms, such as conjugated, azide-free, or ready-to-use, have not been tested. For immunohistology and flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.
Binds to collagen, thrombospondin, anionic phospholipids and oxidized low-density lipoprotein (oxLDL). May function as a cell adhesion molecule. Directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Receptor for thombospondins, THBS1 AND THBS2, mediating their antiangiogenic effects.